Integrated in silico and in vivo approaches reveal naltrexone as a synergistic modulator of TLR4 and μ-opioid receptors restoring redox homeostasis via Nrf2/Keap-1/HO-1 and HIF-1α/VEGF pathways in COPD.

naltrexone - Generic mfg.

Lodonal (naltrexone low dose oral) - Biostax Corp, Statera BioPharma

http://www.ncbi.nlm.nih.gov/pubmed/42635925

Soni; Subhashini; Atul Srivastava; Pratikkumar Gaglani; Vandana Yadav; Vinita Pandey

Aug 25, 2026